Nebenwirkungen · Ozurdex
OZURDEX 700 micrograms intravitreal implant in applicator · Abschnitt 4.8 · PDF-Seite 7
HOS-122533 · Präparat HOS-095531
* indicates adverse reactions considered to be related to the intravitreal injection procedure (the frequency of these adverse reactions is proportional to the number of treatments given). ** in a 24-month real world observational study in the treatment of macular oedema following RVO and non- infectious uveitis affecting the posterior segment of the eye these adverse events were reported more frequently among patients who received >2 injections vs patients who received ≤2 injections; cataract formation (24.7% vs 17.7%), cataract progression (32.0% vs 13.1%), vitreous haemorrhage (6.0% vs 2.0%), and increased IOP (24.0% vs 16.6%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-29T16:00:00Z · SHA-256 53363d650dca503ce72c050813175e5baa834767d0b4c57e771b47a209bcad35 · Passage 5ee70cde5f4c6aa0233c8727a4ce49dca26a281132e92817b141d895f158005d · Zeichen 3227–3865 im Abschnitt